Immix Biopharma, Inc. · NASDAQ:IMMX
Immix Biopharma — Investor Presentation (August 2026)
31 slides from Immix Biopharma's investor presentation, August 2026
Slide 1: Global Leader in Relapsed/Refractory AL Amyloidosis
Global Leader in Relapsed/Refractory AL Amyloidosis This presentation contains clinical data presented at ASH Dec 7, 2025 with a May 2026 update on pages 19-23 August 2026
Slide 2: Disclaimer: Forward Looking Statements & Market Data
Disclaimer: Forward Looking Statements & Market Data This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding Immix Biopharma, Inc.
Slide 3: The moment every doctor and family dreads
The moment every doctor and family dreads… “There’s nothing more we can do.” In AL amyloidosis, that sentence has been delivered to 30,506 patients living in the U.S.
Slide 4: I've been the doctor in that room
I’ve been the doctor in that room. I’ve watched hope disappear. And I couldn’t accept that suffering was “standard of care.” Ilya Rachman, MD, PhD Chief Executive Officer, Founder
Slide 5: When your immune system becomes your killer
When your immune system becomes your killer Normally, antibodies protect us In AL amyloidosis, they go rogue, turning like superheroes. into supervillains that flood the body with toxic light chains.
Slide 6: The Toxic Last Ditch Effort
The Toxic Last Ditch Effort A single FDA approval – a 4-drug combination – exists, for newly diagnosed patients only. And it doesn’t work for everyone. Once relapse hits, there's nothing FDA approved. Then, doctors resort to recycling off-label drugs, knowing they’ll fail again. Note: ~2/3 of patien
Slide 7: AL Amyloidosis Response Rate After The 4-Drug Combination Fails
AL Amyloidosis Response Rate After The 4-Drug Combination Fails 12 PATIENT SERIES RECEIVING SECOND LINE THERAPY Initial Dosing Death due to 11 out of 12 Disease v dFLC Level 1 out of 12 Remission: v No Symptoms Days since treatment → There are no drugs approved in relapsed/refractory AL amyloidosis.
Slide 8: 30,506 Relapsed/Refractory U.S. Patients with No FDA Approved Drugs
AL Amyloidosis: 30,506 Relapsed/Refractory U.S. Patients with No FDA Approved Drugs NXC-201 TARGETS AL AMYLOIDOSIS PLASMA CELLS THAT EXPRESS BCMA ON CELL SURFACE Light chains deposit in organs, damaging organs Light chains produced by Light chains misfold and dysfunctional plasma cells aggregate Hea
Slide 9: We've found a breakthrough to change that hopeless sentence
We’ve found a breakthrough to change that hopeless sentence Our mission is simple: Create medicines that work without destroying the person.
Slide 10: The Science That Enables Our Platform
Ex-NCI/NIH Immix academic researchers ambitiously formulated a thesis: can The Science That Enables Our Platform cell therapy be expanded to a broader patient population, beyond cancer? Result: Sterically-optimized NXC-201 Impeded phosphorylation of ITAM1, added ubiquitination site… led to “digital”
Slide 11: Extraordinary Results in Clinical Trials
Extraordinary Results in Clinical Trials Relapsed/refractory AL Amyloidosis - Market Situation Current Standards of Care NXC-201 0-10% complete response rate 95% complete response rate (standard of care) (ASH 2025 with May 2026 Update) Note: R/R AL current standard of care therapies included: Dara-V
Slide 12: What that can mean for the patient
What that can mean for the patient… Life becomes normal again. A deep breath that reaches the bottom of the lungs. A walk that doesn't end at the mailbox. A normal heartbeat again. 12
Slide 13: The Multi-Billion Dollar Opportunity
The Multi-Billion Dollar Opportunity Prevalence Incidence AL Amyloidosis Overall Survival Existing therapies 30,506 • ~35% of Era 4 (2010-2019) patients on 5,386 Darzalex Era 3 (2000-2009) patients … Of combos ~80% eligible for × Darzalex Subtract 4% which, reach a CR treatment Cardiac stage 5.9 yea
Slide 14: The Road Ahead
The Road Ahead Prior 2Q25 3Q25 4Q25 1Q26 Q3 26 1H 27 ✓ ✓ Secured rights to NXC-201, N-GENIUS platform from ex- U.S. university ✓ Reported ex-U.S. NEXICART-1 AL Amyloidosis data at ASGCT 2023, ASH 2023, ASGCT 2024, ASH 2024, JCO published 2024 Phase 1 All 45 patients ✓ FDA Orphan Drug Designation (OD
Slide 15: Commercial
Commercial 20 high-prescribing Sites in existing Immix clinical trial Commercial launch plan end of 2027 AL Amyloidosis annual sales: ~$1.7bn Note: (4,500 new cases AL) / (SEER New Cases MM in 2025 36,110) = 12.4% * $14bn annual run rate = $1.7bn Note: Future management expected pricing represented
Slide 16: A World Class Team Dedicated To Saving Lives
A World Class Team Dedicated To Saving Lives Ilya Rachman, MD, PhD David Marks, MBBS, PhD Chief Executive Officer Chief Medical Officer Amanda Squires Gabriel Morris Head of Clinical President, Chief Financial Officer Operations Michael Grabow Oleg Evgrafov, Chief Commercial Officer Head of Quality
Slide 17: We believe we are on the brink of turning despair into hope
We believe we are on the brink of turning despair into hope Success here opens the door to treating other serious diseases 17
Slide 18: NEXICART-2 U.S. Relapsed/Refractory AL Amyloidosis Trial
NEXICART-2 U.S. Relapsed/Refractory AL Amyloidosis Trial (NCT06097832) U.S. TRIAL WITH REGISTRATIONAL DESIGN, ENROLLMENT COMPLETED Study design • Open-label, single-arm, multi-site phase 1/2 study • n=45 patients Key criteria Inclusion •AL Amyloidosis patients exposed to at least 1 line of therapy i
Slide 19: NEXICART-2 (U.S.) Baseline Characteristics
NEXICART-2 (U.S.) Baseline Characteristics: Representative of U.S. R/R AL Amyloidosis Patient Population Presented Dec 7, 2025 at ASH with May 2026 update preserved heart function NX2-001 NX2-002 NX2-003 NX2-004 NX2-005 NX2-006 NX2-007 NX2-008 NX2-009 NX2-010 NX2-011 NX2-012 NX2-013 NX2-014 NX2-015
Slide 20: NEXICART-2 (U.S.) Efficacy: Rapid Normalization of Diseased Light Chains
NEXICART-2 (U.S.) Efficacy: Rapid Normalization of Diseased Light Chains within ~First Week Presented Dec 7, 2025 at ASH with May 2026 update dFLC M-Spike Best Response 0% Percentage change in dFLC/M-Spike from baseline -10% -20% -30% -40% -50% -60% -70% -80% -90% -91.13% -93.36% -100% -98.46% -100.
Slide 21: NEXICART-2 (U.S.) Clinical Activity: 95% Complete Responses
NEXICART-2 (U.S.) Clinical Activity: 95% Complete Responses (CR) – 19/20 Patients Subject # NX2-001 NX2-002 NX2-003 NX2-004 NX2-005 NX2-006 NX2-007 NX2-008 NX2-009 NX2-010 NX2-011 NX2-012 NX2-013 NX2-014 NX2-015 NX2-016 NX2-017 NX2-018 NX2-019 NX2-020 Time to response (days) 14 7 15 7 7 7 7 7 7 7 16
Slide 22: NEXICART-2 (U.S.) TEAEs Consistent or Improved Compared to Ex-US Dataset
NEXICART-2 (U.S.) TEAEs Consistent or Improved Compared to Ex-US Dataset • No patient experienced a Grade 5 TEAE across any cohort related to NXC-201 Presented Dec 7, 2025 at ASH with May 2026 update Median Subject NX2-001 NX2-002 NX2-003 NX2-004 NX2-005 NX2-006 NX2-007 NX2-008 NX2-009 NX2-010 NX2-0
Slide 23: Complete Response Rate Improving Over Time
Complete Response Rate Improving Over Time Data Cutoff: April 11, 2025 November 13, 2025 May 14, 2026 with May 2026 update CR RATE: 70% 75% 95% Time to Subject # response NX2- (days) 001 14 CR CR CR 002 7 CR CR CR 003 15 CR CR CR Pending 004 7 (already MRD (-)10-5) CR CR 005 7 CR CR CR 006 7 CR CR C
Slide 24: NEXICART-3 U.S. Newly Diagnosed AL Amyloidosis Trial
NEXICART-3 U.S. Newly Diagnosed AL Amyloidosis Trial PHASE 3 RANDOMIZED CONTROLLED TRIAL –INITIATION PLANNED FOR 1H 2027 Study design • Randomized 1:1, multi-site phase 3 study • Arm A: NXC-201 • Arm B: DaraCyBorD Key criteria Inclusion •Newly diagnosed AL Amyloidosis patients •Cardiac: Mayo stage 3
Slide 25: Global Leader in relapsed/refractory AL Amyloidosis
Global Leader in relapsed/refractory AL Amyloidosis August 2026
Slide 26: NXC-201 Tolerability Drives AL Amyloidosis Leadership
NXC-201 Tolerability Drives AL Amyloidosis Leadership ALL BCMA CAR-TS ARE NOT CREATED EQUAL Median CRS Duration (Days) NXC-201’s short CRS duration, if proven to be safe and NXC-201 effective, makes it uniquely suitable to treat ALA Anito-cel D8 BCMA KLN-1010 /CARTddBCMA /AUTO8 patients (in whom the
Slide 27: NXC-201: Deepest Responses, In Most Heavily Pretreated Population
NXC-201: 1 Deepest Responses, 2 In Most Heavily Pretreated Population NXC-201 Etentamig Linvoseltamab Teclistamab NXC-201: n 20 34 20 52 Later Phase … Phase Phase 2 Phase 1 Phase 2 Retrospective Dosing Frequency 1-Time 24 Months (QW4) Weekly 8W, QW4 40W Monthly Median Prior Lines 4 2 1 2 … in heavil
Slide 28: Market Reference: Commercialization Cost Trend Over Time
Market Reference: Commercialization Cost Trend Over Time $1,200 Yescarta 2017 ~$1bn Gilead highlighted cell therapy business was close to $1,000 break-even in 2024, with sales ~$1.5bn $800 Elevidys COGS + SG&A(1) in Launch Year 2023 $600 $544 (3) (2) $528 $479 Casgevy 2023 Carvykti $400 New launches
Slide 29: NEXICART-1 (Israel): Normalization of Toxic Free Light Chains 30 Days after Dosing
NEXICART-1 (Israel): Normalization of Toxic Free Light Chains 30 Days after Dosing BACKGROUND: IMMIX LICENSED-IN NXC-201 BASED ON EX-U.S. DATA SHOWING PLASMA CELL ELIMINATION (MENTIONED IN NEJM) “An early and deep hematologic response has been found to lead to significantly prolonged survival” – Vai
Slide 30: Up to 91% of AL Amyloidosis Patients Require 2nd Line Therapy within 12 Months
Up to 91% (=18+64+9) of AL Amyloidosis Patients Receiving Frontline Dara-Cy-Bor-D Require 2nd Line Therapy within 12 Months based on peer studies 100 newly diagnosed 18 don’t reach 82 reach (1) 6 cycles 6 cycles(1) (2) 18 (22%) 64 (78%) reach CR(2) don’t reach CR (2) 9 (50%) relapse <12M(2) Note: Ex
Slide 31: Global Leader in relapsed/refractory AL Amyloidosis
Global Leader in relapsed/refractory AL Amyloidosis August 2026
Immix Biopharma — Investor Presentation (August 2026) on 6ix